Navigation Links
High and mighty: first common height gene identified by researchers behind 'obesity gene' finding
Date:9/2/2007

f the HMGA2 gene, a "tall" version and a "short" version. The researchers found that as many as 25% of white Europeans carried two "tall" versions of this particular gene, making them approximately 1cm taller than the 25% of people who carry two "short" versions.

"Height is a typical 'polygenic trait' in other words, many genes contribute towards making us taller or shorter," explains Dr Frayling. "Clearly, our results do not explain why one person will be 6'5" and another only 4'10". This is just the first of many that will be found possibly as many as several hundred."

The exact role that HMGA2 has in growth is unclear, but the researchers believe it is most likely in increased cell production. This may have implications for the development of cancer as tumours occur due to unregulated cell growth. Previous studies have shown an association between height and certain cancers: taller people are statistically more likely to be at risk from cancers, including those found in the prostate, bladder and lung.

"There appears to be a definite correlation between height and some diseases," explains Dr Mike Weedon, lead author on the study. "For example, there are associations between shortness and slightly increased risks of conditions such as heart disease. Similarly, tall people are more at risk from certain cancers and possibly osteoporosis."

Dr Frayling believes that the study has major implications for helping scientists understand how common variations in DNA in the human the genome actually affect us, especially in relation to growth and development.

"Even though improved nutrition means that each generation is getting successively taller, variation in height within a population is almost entirely influenced by our genes," says Dr Frayling. "This fact, coupled with the ease of measuring height, means that height can act as a model trait, allowing us to explore in detail the influence that the genome actually has on our
'/>"/>

Contact: Craig Brierley
c.brierley@wellcome.ac.uk
44-207-611-7329
Wellcome Trust
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. First Vaccine Designed for Africa Cleared for Testing in Humans
2. Infant receives first bloodless liver transplant
3. Oracle Corp. to help build worlds first "Digital Hospital"
4. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
5. First human clone is near
6. First Artificial Heart patient has Major setback
7. First global SARS meet opens
8. Launch Of India’s First Virology Course At Pun
9. FDA approves first pocket-sized EKG machine
10. First head-to-head trials of once weekly Fosamax and Actonel therapies
11. WHO Declares Vietnam First Country to Control SARS
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Cambridge Scientists Archive 500,000th Crystal Structure 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 3Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 4Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 5Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 6Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 7Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 8Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 9Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 10Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 11Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 12Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 13Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 14Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 15Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 16Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 17Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 18Covance Inc Invites You to Join the Webcast of Its Second Quarter 2009 Financial Results Conference Call 50805 1Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease 4686 1Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease 4686 2Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease 4686 3Living Medical Textbook 28TM 29 from Projects In Knowledge 28R 29 50802 1Living Medical Textbook 28TM 29 from Projects In Knowledge 28R 29 50802 2Living Medical Textbook 28TM 29 from Projects In Knowledge 28R 29 50802 3